Barry S. Taus, Partner

T: 212.931.0704 | E:

Barry S. Taus currently represents plaintiffs and class members in major complex class actions including In re Effexor XR Direct Purchaser Antitrust Litigation (D.N.J.); In re Amitiza Antitrust Litigation, No. 21-cv-11057 (D.Mass.) and In re Avandia Marketing, Sales Practices and Products Liability Litigation, MDL. No. 181 (E.D. Pa.).

Mr. Taus has also played significant roles in various antitrust class actions that have been successfully resolved, including In re Glumetza Antitrust Litigation, 19-cv-5822 (N.D.Ca.) (settled for $453 million); In re Opana ER Antitrust Litigation (N.D. Ill.) (partially settled for $145 million); In re Suboxone (Buprenorphine Hydrochloride and Naloxone) Antitrust Litigation (E.D. Pa.) (settled for $385 million); .Marchese v. Cablevision Systems Corp., et al. (settled for over $72 million in settlement benefits plus significant injunctive relief) (lead counsel); Universal Delaware, Inc. v. Ceridian Corp., et al. (settled for $130 million plus significant injunctive relief); Castro, et al. v. Sanofi Pasteur, Inc. (settled for $61 million); In re Wellbutrin XL Antitrust Litigation (partially settled for $37.5 million); In re Skelaxin Antitrust Litigation (settled for $73 million); In re Buspirone Antitrust Litigation (S.D.N.Y.) (settled for $220 million); In re Relafen Antitrust Litigation (D. Mass.) (settled for $175 million); and In re Remeron Antitrust Litigation (D. N.J.) (settled for $75 million).

Mr. Taus has acted as Lead Counsel or Co-Lead Counsel for classes of direct purchasers in a number of major, complex antitrust litigations, including In re Cardizem CD Antitrust Litigation (E.D. Mich.) (settled for $110 million); In re Terazosin Hydrochloride Antitrust Litigation (S.D. Fla.) (settled for $75 million); and In re Tricor Antitrust Litigation (D. Del.) (settled for $250 million).

As Lead Counsel for the direct purchaser class in the Tricor case, Mr. Taus successfully negotiated what was then the largest settlement of any direct purchaser class action alleging impeded generic pharmaceutical competition in the Hatch-Waxman antitrust context ($250 million). Prior to settlement, Mr. Taus was responsible for overseeing all material aspects of the litigation on behalf of
the direct purchaser class, including the extensive research leading to the initial complaint, analyzing thousands of pages of discovery documents and taking numerous depositions to marshal evidence to support plaintiffs’ theories relating to liability, antitrust impact, causation, monopoly power and class certification, retaining and working closely with numerous experts, and ultimately preparing for and proceeding to trial.

In addition to his antitrust experience, Mr. Taus took a central, active role in numerous stockholder class action and derivative actions. These actions included Rebenstock v Fruehauf Trailer Corp.; In re Par Pharmaceutical Securities Litigation; In re F&M Distributors, Inc. Securities Litigation; In re Taxable Municipal Bond Litigation; In re Bay Financial Securities Litigation; and Sanders v. Wang, et. al (resulting in recovery from certain senior executives of stock valued in excess of $225 million for the benefit of Computer Associates). Furthermore, Mr. Taus has successfully played a leading role in various complex consumer class actions, including Cicarell v. Provident Mutual Life Ins. Co. (sales practice litigation settled for $45 million) and Provident Demutualization Litigation (enjoined demutualization that would have harmed policyholders).

Mr. Taus graduated cum laude from the State University of New York at Albany in 1986 with a Bachelor of Science degree in Accounting. Mr. Taus graduated from Brooklyn Law School in 1989, and is admitted to the Bar of the State of New York, as well as the United States District Court for the Southern District of New York and the United States Courts of Appeals for the Second and Eleventh Circuits. He is also a member of the New York State Bar Association and the American Bar Association.

Scroll to Top